Cytokine Profile After Lung Transplantation: Correlation With Allograft Injury Amit Mathur, MD, Maher Baz, MD, E. Denmark Staples, MD, Mark Bonnell, MD, Jerry M. Speckman, MD, Phillip J. Hess, MD, Charles T. Klodell, MD, Daniel G. Knauf, MD, Lyle L. Moldawer, PhD, Thomas M. Beaver, MD The Annals of Thoracic Surgery Volume 81, Issue 5, Pages 1844-1850 (May 2006) DOI: 10.1016/j.athoracsur.2005.11.053 Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Experimental design. (ELISA = enzyme-linked immunoassay; h = hour; IL = interleukin; PA = pulmonary arterial; PGF = primary graft failure; PLTRE = post–lung transplant reperfusion edema; SA = systemic arterial; TNF-α = tumor necrosis factor alpha.) The Annals of Thoracic Surgery 2006 81, 1844-1850DOI: (10.1016/j.athoracsur.2005.11.053) Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Interleukin-6 (IL-6) appearance in patients with clinically severe (PGF; n = 4), moderate (PLTRE; n = 6), and no allograft reperfusion injury (n = 11). (Diamonds = PGF SA; squares = PGF PA; triangles = PLTRE SA; X = PLTRE PA; X with hatch mark = no injury SA; X in box = no injury PA.) *Indicates statistically distinct profile of patients with PGF over PLTRE and no allograft reperfusion injury (p < 0.01). (h = hours; PA = pulmonary arterial; PGF = primary graft failure; PLTRE = post–lung transplant reperfusion edema; SA = systemic arterial.) The Annals of Thoracic Surgery 2006 81, 1844-1850DOI: (10.1016/j.athoracsur.2005.11.053) Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Interleukin-8 (IL-8) appearance in patients with clinically severe (PGF; n = 4), moderate (PLTRE; n = 6), and no allograft reperfusion injury (n = 11). (Diamonds = PGF SA; squares = PGF PA; triangles = PLTRE SA; X = PLTRE PA; X with hatch mark = no injury SA; X in box = no injury PA.) *Indicates statistically distinct profile of patients with PGF over PLTRE and no allograft reperfusion injury (p < 0.01). (h = hours; PA = pulmonary arterial; PGF = primary graft failure; PLTRE = post–lung transplant reperfusion edema; SA = systemic arterial.) The Annals of Thoracic Surgery 2006 81, 1844-1850DOI: (10.1016/j.athoracsur.2005.11.053) Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions
Fig 4 Interleukin-10 (IL-10) appearance in patients with clinically severe (PGF; n = 4), moderate (PLTRE; n = 6), and no allograft reperfusion injury (n = 11). (Diamonds = PGF SA; squares = PGF PA; triangles = PLTRE SA; X = PLTRE PA; X with hatch mark = no injury SA; X in box = no injury PA.) *Indicates statistically distinct profile of patients with PGF over PLTRE and no allograft reperfusion injury (p < 0.01). (h = hours; PA = pulmonary arterial; PGF = primary graft failure; PLTRE = post–lung transplant reperfusion edema; SA = systemic arterial.) The Annals of Thoracic Surgery 2006 81, 1844-1850DOI: (10.1016/j.athoracsur.2005.11.053) Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions
Fig 5 Interleukin-6 (IL-6) appearance in the 6 lung transplant recipients who were placed on cardiopulmonary bypass (CPB). (Diamonds = PGF SA; squares = PGF PA; triangles = PLTRE SA; X = PLTRE PA; X with hatch mark = no injury SA; X in box = no injury PA.) (h = hours; PGF = primary graft failure [n = 4]; PLTRE = post–lung transplant reperfusion edema [n = 1]; no injury [n = 1].) The Annals of Thoracic Surgery 2006 81, 1844-1850DOI: (10.1016/j.athoracsur.2005.11.053) Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions